invasive disease-free survival
Figure 2 · Panel iDFS
Panel iDFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching, A Bardia, S Chia, S-A Im, M Martin, B Xu, C H Barrios, M Untch, R Moroose, S A Hurvitz, G N Hortobagyi, D J Slamon, F Visco, G Spera, J P Zarate, D Halligan, Z Li, S Loi
ESMO Open 10(11) 105858
BACKGROUND: At the primary efficacy analysis of the NATALEE phase III trial, ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant improvement in invasive disease-free survival (iDFS) versus NSAI alone in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC). Continued follow-up of efficacy outcomes is important in assessing the durability of treatment benefit. We report 5-year estimates of efficacy outcomes, including an udpated analysis of overall survival (OS). PATIENTS AND METHODS: Eligible patients included pre/postmenopausal women and men with HR-positive/HER2-negative EBC and anatomic stage IIA (N1 or N0 with high-risk factors), IIB, or III disease. Patients were randomized 1 : 1 to ribociclib 400 mg/day (3 weeks on/1 week off for 3 years) + NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 5 years) or NSAI alone. Premenopausal women and men received goserelin. The primary endpoint was iDFS, and secondary/exploratory endpoints included distant disease-free survival, recurrence-free survival, distant recurrence-free survival, and OS. RESULTS: With a median iDFS follow-up of 55.4 months, ribociclib + NSAI demonstrated persistent iDFS benefit versus NSAI alone [hazard ratio 0.716, 95% confidence interval (CI) 0.618-0.829, nominal one-sided log-rank P < 0.0001]. Absolute iDFS improvement between treatment arms increased from the 3- (Δ2.7%) to the 5-year (Δ4.5%) time points. Persistent benefit over time was also observed across subgroups [including N0 patients (hazard ratio 0.606, 95% CI 0.372-0.986)] and secondary/exploratory endpoints. As OS continues to mature, numerical improvement in favor of ribociclib was observed (hazard ratio 0.800, 95% CI 0.637-1.003, nominal one-sided log-rank P = 0.026). CONCLUSIONS: This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.
3 个 Figure · 5 个 KM 面板
Figure 2 Kaplan–Meier survival curve of iDFS in the ITT population. CI, confidence interval; IDFS, invasive disease-free survival; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib. a The difference between percentages does not equal 2.7 due to rounding.
Figure 2 · Panel iDFS
Panel iDFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 Kaplan-Meier survival curves. Kaplan–Meier survival curves of DDFS (A), DRFS (B), and RFS (C) in the ITT population. CI, confidence interval; DDFS, distant disease-free survival; DRFS, distant recurrence-free survival; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib; RFS, recurrence-free survival.
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel C
Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 Kaplan–Meier survival curve of OS in the ITT population. CI, confidence interval; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; RIB, ribociclib.
Figure 5 · Panel Figure_5_Kaplan_Meier_survival_curve_of_OS_in_the_ITT_population.
Panel Figure_5_Kaplan_Meier_survival_curve_of_OS_in_the_ITT_population. 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。